J. Fletcher
Journal of Clinical Oncology · 2000–2010
A researcher in the Science corpus: 14 papers; trusts 0 researchers and is trusted by 2 researchers here, as inferred from the citation graph.
Who trusts J. Fletcher
- Christopher Corless (in Gastroenterology)
- M. Heinrich (in Gastroenterology)
Papers from J. Fletcher's perspective
Ordered by how strongly the researchers J. Fletcher trusts endorse each paper. Same corpus, a different order for every researcher.
- Diagnosis of gastrointestinal stromal tumors: A consensus approach. (Human Pathology)
- Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase* (Journal of Biological Chemistry)
- Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. (Journal of Clinical Oncology)
- Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. (Annals of Surgery)
- Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. (New England Journal of Medicine)
- Nonparametric Estimation from Incomplete Observations
- TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. (American Journal of Pathology)
- Anticancer drugs: To the rescue? (Nature reviews. Drug discovery)
- Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
- The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website (British Journal of Cancer)
Their papers
- PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. (2000) — 698 citations
- Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations (2010) — 619 citations
- The landscape of somatic copy-number alteration across human cancers (2010) — 3,892 citations
- Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. (2008) — 728 citations
- Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. (2008) — 988 citations
- High-throughput oncogene mutation profiling in human cancer (2007) — 1,054 citations
- Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. (2006) — 805 citations
- Biology of gastrointestinal stromal tumors. (2004) — 1,198 citations
- The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. (2003) — 672 citations
- PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors (2003) — 2,423 citations
- Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. (2003) — 2,287 citations
- Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. (2002) — 4,306 citations
- KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. (2001) — 1,009 citations
- STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications (2001) — 704 citations